Program for all days

Better Kidney Health

The Interconnected Kidney

Preserving Kidney Health

The Smart Kidney

Plenary Sessions

Pre-congress Courses

Spotlight Sessions

Special Sessions

Global Kidney Policy Forum

Welcome Reception

Tropical Networking

Poster Sessions

28 March 2026

Time	Session

8:30 a.m. 10 a.m.	Renal Pathology Course: Transplantation Related Kidney Diseases Update on Banff Transplant Pathology Classification AgnesFogo Speaker agnes.fogo@vanderbilt.eduUnited States Kidney Lesions Following Stem Cell Transplantation SuryaSeshan Speaker svs2002@med.cornell.eduUnited States Digital Pathology and Artificial Intelligence Applications in Kidney Transplant Pathology PeterBoor Speaker pboor@ukaachen.deGermany Q&A Session 301 - 302																		Tools to Strengthen Global Kidney Trials: Design, Innovative Endpoints, and Communication Across Regions 1 Breaking New Ground in Clinical Trials BrendanSmyth Chair brendanjsmyth@gmail.comAustralia High level summary of the two previous webinars High Level Summary of the Two Previous Webinars AdeeraLevin Speaker alevin@providencehealth.bc.caCanada Designing Trials for Inclusivity and Generalizability Andrea Viecelli Speaker andrea.viecelli@usz.chSwitzerland Trials Without Borders RathikaKrishnasamy Speaker Rathika.Krishnasamy@health.qld.gov.auAustralia Use of Novel Tools in Kidney Research Pedro HenriqueFranca Gois Speaker pedro.francagois@health.nsw.gov.auAustralia Q&A Session 303																		Onco-Nephrology Course: Acute Kidney Injury (AKI) in the Cancer Patient AKI Due to Chemotherapy Diana CarolinaVargas Angel Speaker dcvargas@husi.org.coColombia AKI Due to Targeted Therapy MotokoYanagita Speaker motoy@kuhp.kyoto-u.ac.jpJapan AKI Due to Immunotherapy Maria JoseSoler Speaker mjsoler01@gmail.comSpain Roundtable Discussion KenarJhaveri Moderator Kjhaveri@northwell.eduUnited States 304																		Conservative Kidney Management: What Are Kidney Supportive Care (KSC) and Conservative Kidney Management (CKM)? PeaceBagasha Chair bagashap@gmail.comUganda SaraDavison Chair sara.davison@ualberta.caCanada Introduction to concepts/principles of Kidney Supportive Care and Conservative Kidney Management SaraDavison Speaker sara.davison@ualberta.caCanada Joint Talk: Planning for conservative kidney management - A Tale of Two Cities BarnabyHole Speaker barnaby.hole@bristol.ac.ukUnited Kingdom PeaceBagasha Speaker bagashap@gmail.comUganda Essential Communication Skills for Successful Advance Care Planning BarnabyHole Speaker barnaby.hole@bristol.ac.ukUnited Kingdom Q&A Session 311 - 312																		Local Kidney Registries in Action: Regional Insights and Innovations Kidney Registries in Action: global collaboration to improve access to treatment and patient outcomes GeorginaIrish Chair georgina@anzdata.org.auAustralia Welcome FergusCaskey Speaker Fergus.Caskey@bristol.ac.ukUnited Kingdom Introduction ToshihideNaganuma Speaker m9643361@omu.ac.jpJapan Lessons From Developing a National Hemodialysis Registry in Nepal DibyaSingh Shah Speaker dibyasingh@hotmail.comNepal Status of Dialysis Therapy in Mongolia: Insights From the National Dialysis Registry AdiyaSaruultuvshin Speaker saruultuvshin@mnums.edu.mnMongolia Applying National Kidney Registry Data to Japanese Clinical Practice Guidelines JunichiHoshino Speaker hoshino.junichi@twmu.ac.jpJapan Panel Discussion 313 - 314																		Annual Review of Nephrology Course 1 KenjiMatsui Chair kematsui@gmail.comUnited States MitchellRosner Chair MHR9R@hscmail.mcc.virginia.eduUnited States SabineKaram Chair sabinejkaram@gmail.comUnited States Update on Diabetes Kidney Disease Management SunitaBavanandan Speaker sbavanandan@gmail.comMalaysia New Drugs for Polycystic Kidney Disease MichelChonchol Speaker Michel.Chonchol@comcast.netUnited States B Cell Targeted Therapies for Glomerular Diseases RichardLafayette Speaker czar@stanford.eduUnited States Q&A Session 501 - 502																		Interventional Nephrology Course: Dialysis Access in Action: Mapping, Cannulation, and Volume Assessment Tunneled Central Venous Catheter Placement and Troubleshooting: Simulation-based Training BernardoMoguel González Speaker bernardomoguel@hotmail.comMexico Hoon SukPark Speaker cttailor@catholic.ac.krSouth Korea Hemodialysis Access: Venous Mapping, AVF Assessment, Ultrasound Maturity Evaluation, and Simulation-guided Cannulation ToshihideNaganuma Speaker m9643361@omu.ac.jpJapan VandanaNiyyar Speaker vniyyar@emory.eduUnited States Volume Assessment Using Lung Ultrasound and Inferior Vena Cava Imaging BhavnaBhasin-Chhabra Speaker bhasin-chhabra.bhavna@mayo.eduUnited States EduardoArgaiz Speaker lalo.argaiz@gmail.comMexico Q&A Session 503
10:30 a.m. 12 p.m.	Renal Pathology: Native Kidney Disease Pathology – Advances/Update Spectrum of IgG4 Related Kidney Diseases TakakoSaeki Speaker tsaeki04@gmail.comJapan Spectrum of Tropical Infections and Renal Lesions in Parasitic Diseases AhmedKalebi Speaker drkalebi@ahmedkalebi.comKenya From Uncertainty to Diagnosis: Genomics in Undetermined Kidney Disease LaurentMesnard Speaker laurent.mesnard@aphp.frFrance Q&A Session 301 - 302																		Tools to Strengthen Global Kidney Trials: Design, Innovative Endpoints, and Communication Across Regions 2 Global Trials Perspectives KatherineTuttle Chair Katherine.Tuttle@providence.orgUnited States MegumiOshima Chair mgm_oshima@yahoo.co.jpJapan VivekKumar Chair enigma165@yahoo.co.inIndia Japanese Perspective MegumiOshima Speaker mgm_oshima@yahoo.co.jpJapan African Perspective RobertKalyesubula Speaker rkalyesubula@gmail.comUganda Insights on Consent Challenges in Low and Middle-income Countries ShuchiAnand Speaker sanand2@stanford.eduUnited States Closing the Loop: Returning Results to Participants: Why and How AdeeraLevin Speaker alevin@providencehealth.bc.caCanada BillWang Speaker billwang1968@yahoo.comHong Kong, China Q&A Session 303																		Onco-Nephrology Course: Electrolyte Disturbances in the Cancer Patient Hyponatremia in Patients with Cancer SanjeevNair Speaker docsvn@gmail.comIndia Hypercalcemia in Patients with Cancer MohamedHassanein Speaker hassanein.mh@gmail.comEgypt Hypomagnesemia and Hypophosphatemia in Patients With Cancer JolantaMalyszko Speaker jolmal@poczta.onet.plPoland Roundtable Discussion KenarJhaveri Moderator Kjhaveri@northwell.eduUnited States 304																		Conservative Kidney Management: How to deliver CKM - A Focus on Symptom Management Managing Restless Legs, CKD-Associated Pruritus, and Insomnia in Conservative Kidney Management BrendanSmyth Speaker brendanjsmyth@gmail.comAustralia Management of Pain in Conservative Kidney Management PramoteEuasobhon Speaker pramoteo@hotmail.comThailand Management of Fatigue and Mental Health in Conservative Kidney Management PeaceBagasha Speaker bagashap@gmail.comUganda Q&A Session 311 - 312																		Real-World Data and Registries in Clinical Research AlejandroFerreiro-Fuentes Chair aferreirofuentes@gmail.comUruguay FergusCaskey Chair Fergus.Caskey@bristol.ac.ukUnited Kingdom Introduction GeorginaIrish Speaker georgina@anzdata.org.auAustralia Embedding Randomization in a National CKD Registry: The SACK Apixaban Study MarieEvans Speaker marie.evans@ki.seSweden Platform Trials Using Routine Data for Pediatric Rare Diseases DorotheaNitsch Speaker dorothea.nitsch@lshtm.ac.ukUnited Kingdom Lessons Learned From Hemodialysis and Peritoneal Dialysis Trials: ANZDATA Insights StephenMcdonald Speaker stephen.mcdonald@sa.gov.auAustralia Q&A 313 - 314																		Annual Review of Nephrology Course 2 SolaAoun Bahous Chair sola.bahous@gmail.comLebanon Yoshihito Nihei Chair y-nihei@juntendo.ac.jpJapan Linking Renal Pathology to Kidney Function Jonathan Barratt Speaker jb81@leicester.ac.ukUnited Kingdom Management of C3 Glomerulopathy: From Diagnosis to Targeted Therapy ShoichiMaruyama Speaker marus@med.nagoya-u.ac.jpJapan Update on the Cardio-Kidney Metabolic Syndrome SolaAoun Bahous Speaker sola.bahous@gmail.comLebanon Q&A Session 501 - 502																		Interventional Nephrology Course: Ultrasound in Nephrology- From Diagnosis to Intervention Diagnostic Ultrasound of the Kidneys and Bladder ToshihideNaganuma Speaker m9643361@omu.ac.jpJapan VandanaNiyyar Speaker vniyyar@emory.eduUnited States Kidney Biopsy BernardoMoguel González Speaker bernardomoguel@hotmail.comMexico Hoon SukPark Speaker cttailor@catholic.ac.krSouth Korea Volume Assessment Using Cardiac Ultrasound and the VExUS Score BhavnaBhasin-Chhabra Speaker bhasin-chhabra.bhavna@mayo.eduUnited States EduardoArgaiz Speaker lalo.argaiz@gmail.comMexico Q&A Session 503
11 a.m. 11:15 a.m.	Professor Donal O'Donoghue Global Kidney Policy Forum: Opening Remarks A Turning Point for Kidney Health: Leveraging the WHO Resolution for Regional and National Impact MarcelloTonelli Speaker cello@ucalgary.caCanada The GKPF and the 10 Global Kidney Health Recommendations IfeomaUlasi Speaker ifeomaulasi@yahoo.co.ukNigeria 315
11:15 a.m. 12:05 p.m.	Professor Donal O'Donoghue Global Kidney Policy Forum: Japan’s CKD Strategy in Action — Lessons From an Aging Society IfeomaUlasi Chair ifeomaulasi@yahoo.co.ukNigeria Addressing Kidney Disease in Japan: How Does the National Policy Meet Global Commitments YosukeYamada Speaker yamada-yousuke.y66@mhlw.go.jpJapan Transforming Kidney Care Through National Strategy: A Nephrologist Perspective NaokiKashihara Speaker kashinao@med.kawasaki-m.ac.jpJapan Living the Strategy: A Patient’s Perspective on Navigating Kidney Care in Japan TakeshiShukunobe Speaker takeshi.shukunobe@ppecc.jpJapan Financing Kidney Health: Sustainable and Innovative National Approaches YusukeSuzuki Speaker yusuke@juntendo.ac.jpJapan Q&A 315
12:05 p.m. 12:55 p.m.	Professor Donal O'Donoghue Global Kidney Policy Forum: Advancing Kidney Health Across North and East Asia: Regional Challenges and Opportunities Muhammad IqbalAbdul Hafidz Moderator fmeu6038@gmail.comMalaysia Integrating Kidney Health into NCD Strategies: A Regional Perspective from WHO HuongTran Speaker tranh@who.intVietnam Data-driven Kidney Health: The Taiwan Experience Mai SzuWu Speaker maiszuwu@gmail.comTaiwan Advancing Kidney Disease Prevention and Care in China LuxiaZhang Speaker zhanglx@bjmu.edu.cnChina Addressing Kidney Disease through the National Health Plan 2030 (HP2030) Kook-HwanOh Speaker khoh@snu.ac.krSouth Korea Bridging the Gap Between Policy and Patient Reality ManvirVictor Speaker jmanvir@gmail.comMalaysia Q&A 315
12:15 p.m. 1:15 p.m.	Renal Pathology Course: Clinical-Pathologic Correlation Case Presentations Case Discussion 1 AgnesFogo Speaker agnes.fogo@vanderbilt.eduUnited States Case Discussion 2 SuchinWorawichawong Speaker suchin.wor@mahidol.ac.thThailand Case Discussion 3 Mineaki Kitamura Speaker minekitamura@nagasaki-u.ac.jpJapan Q&A 301 - 302																		Tools to Strengthen Global Kidney Trials: Design, Innovative Endpoints, and Communication Across Regions 3 Implementation Science in Action MichaelWalsh Chair lastwalsh1975@gmail.comCanada Practical Aspects of Implementation Science; Hands-on Studies Tae WonYi Speaker taewon.yi@gmail.comCanada Value of Implementation Science RukshanaShroff Speaker Rukshana.Shroff@gosh.nhs.ukUnited Kingdom Implementation Science in Digital Health: Clinical Trials Using Mobile Applications for Patient Interventions YusukeSakaguchi Speaker sakaguchi@kid.med.osaka-u.ac.jpJapan Take Home Messages MegJardine Speaker meg.jardine@sydney.edu.auAustralia 303																		Onco-Nephrology Course: Onco-Nephrology in Special Populations Onco-nephrology in the Kidney Transplant Population RobertCarroll Speaker robert.carroll@health.sa.gov.auAustralia Onco-Hypertension: Mechanisms, Monitoring, and Management SabineKaram Speaker sabinejkaram@gmail.comUnited States GFR Estimation in Patients With Cancer ShuchiAnand Speaker sanand2@stanford.eduUnited States Q&A and Final Remarks KenarJhaveri Moderator Kjhaveri@northwell.eduUnited States 304																		Conservative Kidney Management: How to deliver CKM - Why It Is Everybody's Business Managing Metabolic Complications of Kidney Failure in Conservative Kidney Management SaraDavison Speaker sara.davison@ualberta.caCanada End-of-Life Care in Conservative Kidney Management: Symptom-focused Approaches NandiniVallath Speaker aanandini@gmail.comIndia Q&A Session 311 - 312																		From Definition to Data: Advancing Standardisation in CKD Registries MarieEvans Chair marie.evans@ki.seSweden StephenMcdonald Chair stephen.mcdonald@sa.gov.auAustralia Why We Need Standardised Data in CKD Registries AlejandroFerreiro-Fuentes Speaker aferreirofuentes@gmail.comUruguay UK Experience in Harmonizing Routine CKD Data for Research SamiraBell Speaker stbell@dundee.ac.ukUnited Kingdom Overcoming Barriers to Global CKD Data Standardization JamesWetmore Speaker james.wetmore@hcmed.orgUnited States Q&A 313 - 314																		Annual Review of Nephrology Course 3 BiancaDavidson Chair bianca.davidson@gmail.comSouth Africa SHOICHIMARUYAMA Chair mrsho111@gmail.comJapan How Do I Manage Hepatorenal Syndrome? Lori-AnnFisher Speaker lori2k15@gmail.comJamaica How Do I Manage: Checkpoint Inhibitor-associated AKI MitchellRosner Speaker MHR9R@hscmail.mcc.virginia.eduUnited States Q&A Session 501 - 502																		Interventional Nephrology Course: PD Catheter Simulation Introduction BernardoMoguel González Speaker bernardomoguel@hotmail.comMexico 503
12:55 p.m. 1 p.m.	Professor Donal O'Donoghue Global Kidney Policy Forum: Closing Remarks and Next Steps IfeomaUlasi Speaker ifeomaulasi@yahoo.co.ukNigeria 315
2 p.m. 3:30 p.m.	Plenary Lecture 1: Donald Seldin Lecture - Dynamics of the Function and Regulation of the Endoplasmic Reticulum and WCN'26 Opening Ceremony Jean Hamburger Award SunitaBavanandan Chair sbavanandan@gmail.comMalaysia KazutoshiMori Speaker mori.kazutoshi.8r@kyoto-u.ac.jpJapan TakashiKadowaki Speaker t-kadowaki@toranomon.kkr.or.jpJapan Main Hall
3:45 p.m. 4:45 p.m.	The Gut–Kidney Axis in CKD: Mechanistic Insights and Therapeutic Perspectives The Gut as a Central Hub of Inter-Organ Cross-Talk in Chronic Kidney Disease LaetitiaKoppe Speaker laetitia.koppe@chu-lyon.frFrance Deciphering Gut Dysbiosis: Is It Age or Kidney Disease? JohannesHolle Speaker Johannes.Holle@med.uni-tuebingen.deGermany Inflammation Under Neural Control: The Gut-Brain-Kidney Triad in Acute Kidney Injury MarkOkusa Speaker mdo7y@virginia.eduUnited States Q&A 301 - 302														Cutting edge science in nephrotic syndrome/FSGS Genetics of Nephrotic Syndrome and FSGS DanielGale Speaker d.gale@ucl.ac.ukUnited Kingdom Immunology of Podocyte Injury: Nephrotic Syndrome and FSGS Hans-JoachimAnders Speaker hjanders@med.uni-muenchen.deGermany New Translational Insights in B-cell Targeted Therapies in Nephrotic Syndrome/FSGS NicolaTomas Speaker n.tomas@uke.deGermany Q&A Session 303														AI in Kidney Care: From Predictive Models to Pathology Support Korean Society of Nephrology Named Session Hyeong Cheon Park Chair amp97@yuhs.acKorea Deep Learning in CKD Risk Stratification Using AI to Predict AKI in Critical Care Nephrology Yu HuiZHANG Speaker zhangyuhui9107@foxmail.comChina AI-enhanced Analysis of Kidney Biopsies IsaoMatsui Speaker matsui@kid.med.osaka-u.ac.jpJapan Q&A 304														Expanding Kidney Care Access Through Non-physician Workforce Models Becky MingyaoMa Chair mymbecky@gmail.comHong Kong, China Tae WonYi Chair taewon.yi@gmail.comCanada Non-physician Healthcare Models in CKD Care: What They Are and How to Build Them Carmen ElenaCervantes Speaker ccervan2@jhmi.eduUnited States Empowering Primary-level Healthcare Providers Through Targeted Kidney Health Education: Lessons from India PritiMeena Speaker pritimn@gmail.comIndia Survey of Non-physician Healthcare Workers on Early CKD Detection: Preliminary Results Ana CatalinaAlvarez Elias Speaker anacatalina.alvarezelias@rriny.comUnited States Expanding CKD Care Capacity Using Non-physician Providers in Fiji Yogeshni Chandra Speaker chandra_yogi@yahoo.comFiji Building Community Kidney Care in Nigeria Through Non-physician Healthcare Workers ChimezieOkwuonu Speaker getchimezie@yahoo.comNigeria Curated Discussion 311 - 312														ISN-WIN- WIN India-WIN Africa Joint Session: Bridging the Gap: Addressing Gender Disparities in Kidney Health Women in Nephrology (WIN): Breaking Barriers in Kidney Health - Gender Disparities in CKD and Dialysis MalaSachdeva Speaker msachdeva@northwell.eduUnited States WIN-India: The Social Construct of Organ Donation -Are Women Forced to Donate? PriyamvadaP S Speaker priyamvadaps@gmail.comIndia WIN-Africa: Trials And Tribulations: Improving Randomized Controlled Trials- How Reporting Outcomes By Sex/gender Can Make A Difference, And Barriers To Inclusion KhalidaBulhan - Soki Speaker drkbsoki@gmail.comKenya Q&A 313 - 314														Advancing Sustainable Kidney Care: Evidence and Implementation The Latest Evidence on the Environmental Impact of Kidney Care VivekanandJha Speaker vjha@georgeinstitute.org.inIndia Sustainable Kidney Care Using the GREEN-K Toolkit Winston Wing ShingFung Speaker winstonwsfung@hotmail.comHong Kong, China Greening Kidney Care in Low- and Middle-income Countries MohamedBen Hmida Speaker mohamedbenhmida148@gmail.comTunisia Q&A Session 315														The Future of AKI Care: New Therapies, Recovery Paradigms, and Global Equity Chinese Society of Nephrology Named Session Global Burden of AKI: Challenges and Barriers NattachaiSrisawat Speaker nattachai.sr@chula.ac.thThailand AKI and proteinuria Chi-yuanHsu Speaker Chi-yuan.Hsu@ucsf.eduUnited States Novel Treatments in Septic Acute Kidney Injury Kent Doi Speaker kentdoi@m.u-tokyo.ac.jpJapan New Strategies to Promote Recovery After AKI MarliesOstermann Speaker m.ostermann@nhs.netUnited Kingdom Q&A 501 - 502														CKD-MBD in Practice: Challenges, Controversies, and Consensus The Evolving Biology of CKD-MBD: Implications for Clinical Care MarcVervloet Speaker Marc.Vervloet@radboudumc.nlNetherlands Key Outcomes From the KDIGO CKD-MBD Controversies Conference Growing Up With Chronic Kidney Disease-Mineral and Bone Disorder: Pediatric Challenges RukshanaShroff Speaker Rukshana.Shroff@gosh.nhs.ukUnited Kingdom Q&A Session 503														HIT! High Impact Clinical Trials 1 DavidWheeler Chair d.wheeler@ucl.ac.ukUnited Kingdom KatherineTuttle Chair Katherine.Tuttle@providence.orgUnited States REMODEL Trial Overview: Framework and Key Outcomes PetterBjornstad Speaker pettermb@uw.eduUnited States Semaglutide Improves Kidney Outcomes Regardless Of SGLT2i Use In People With Chronic Kidney Disease And Type 2 Diabetes: Post-hoc Analysis The Remodel Trial DavidCherney Speaker david.cherney@uhn.on.caCanada Aldosterone Blockade for Health Improvement Evaluation in End-stage Renal Disease Trial (ACHIEVE) MichaelWalsh Speaker lastwalsh1975@gmail.comCanada B-cell Targeted Therapy for Idiopathic Nephrotic Syndrome: Results of the Phase III Global Multicenter Inshore Trial Evaluating Efficacy and Safety of Obinutuzumab vs Mycophenolate Mofetil JulienHogan Speaker julien.hogan2@aphp.frFrance Q&A Session Main Hall
5 p.m. 6 p.m.	Young Nephrologists Quiz-a-Thon IV: Japan edition Spotlight Stage 2
5:30 p.m. 6:30 p.m.	Moderated Poster Session Exhibition Hall
6 p.m. 6:45 p.m.	Spotlight on ISN-GKHA: Tracking a Decade of Global Kidney Health Progress Tracking the Evolution of Kidney Health Systems: Insights from ISN-GKHA 2017–2024 GeorginaIrish Speaker georgina@anzdata.org.auAustralia From Data to Action: How the ISN-GKHA Map Drives Policy and Advocacy MarinaWainstein Speaker marinawainstein@outlook.comArgentina Looking Ahead: Priorities and Plans for the ISN-GKHA 2027 Edition AminuBello Speaker aminu1@ualberta.caCanada Spotlight Stage 1																																																															ISN Community Film Event: Kidney Stories from Around the World Spotlight Stage 2

29 March 2026

Time	Session

8:10 a.m. 9:10 a.m.	Industry Symposium 5 HiddoLambers Heerspink Chair H.J.Lambers.Heerspink@umcg.nlNetherlands NaokiKashihara Chair kashinao@med.kawasaki-m.ac.jpJapan Clinical impacts and importance of minimizing drug approval delay (include approval process in US/Europe) NaokiKashihara Speaker kashinao@med.kawasaki-m.ac.jpJapan HCE (hierarchical composite end points) and eGFR slope, as potential solutions to delays in approval HiddoLambers Heerspink Speaker H.J.Lambers.Heerspink@umcg.nlNetherlands Bridging Academia and Regulators in Kidney Drug Development: Insights from Japan MototsuguTanaka Speaker mototsugu.tanaka@gmail.comJapan Panel Discussion DustinLittle Chair dustin.little@astrazeneca.comUnited States HiddoLambers Heerspink Speaker H.J.Lambers.Heerspink@umcg.nlNetherlands MototsuguTanaka Speaker mototsugu.tanaka@gmail.comJapan NaokiKashihara Speaker kashinao@med.kawasaki-m.ac.jpJapan 301 - 302																																																																Industry Symposium 3 AkiraNishiyama Chair nishiyama.akira@kagawa-u.ac.jpJapan MarikoMiyazaki Chair mamiyaza@venus.dti.ne.jpJapan Urinary Uric Acid Excretion and Kidney Outcome YOSHITAKAISAKA Speaker isaka@kid.med.osaka-u.ac.jpJapan Uric Acid and Progression of DKD JunWada Speaker junwada@okayama-u.ac.jpJapan 304																																																																Industry Symposium 1 MasaomiNangaku Chair mnangaku@m.u-tokyo.ac.jpJapan Advanced Data Science in CKD Management YuichiroYano Speaker y.yano@juntendo.ac.jpJapan An Integrated Approach to Cardio-Renal-Metabolic Disorders : Addressing Hypertension and Dyslipidemia KOUICHITAMURA Speaker tamukou@yokohama-cu.ac.jpJapan 315																																																																Industry Symposium 6 Jonathan Barratt Chair jb81@leicester.ac.ukUnited Kingdom What makes IgA pathogenic in IgA nephropathy? YusukeSuzuki Speaker yusuke@juntendo.ac.jpJapan The role of B Cells in IgA nephropathy HeatherReich Speaker Heather.Reich@uhn.caCanada Targeting pathogenic IgA in IgA nephropathy Jonathan Barratt Speaker jb81@leicester.ac.ukUnited Kingdom 501 - 502																																																																Industry Symposium 4 Tak Mao, DanielChan Chair dtmchan@hku.hkHong Kong, China Intestinal Phosphate Absorption Mechanisms UpToDate -Tenapanor and Future Perspectives- HirokoSegawa Speaker segawa@tokushima-u.ac.jpJapan CKD-MBD Guideline Revision in Japan: The Journey and Global Implications HirotakaKomaba Speaker hkomaba@tokai.ac.jpJapan 503																																																																Industry Symposium 2 KaoriHayashi Chair kaorihayashi@keio.jpJapan Impact of Anti-Nephrin Antibodies: An Updated Understanding of the Pathogenesis of Nephrotic Syndrome TomokoHorinouchi Speaker tomoko.hatono@gmail.comJapan Recent Advances in Immunosuppressive Therapy for Refractory Nephrotic Syndrome in Children RikuHamada Speaker hamariku@gmail.comJapan 303
9:25 a.m. 10:55 a.m.	Hypertension Updates: New Rules, Tools, Paths and Plans New Rules: Global Updates in Blood Pressure Guidelines TaraChang Speaker tichang@stanford.eduUnited States What Nephrologists Need to Know About Novel Antihypertensive Treatments Seung HyeokHan Speaker hansh@yuhs.acSouth Korea Implementing the Global Hearts Program to Improve Population Blood Pressure Control SwapnilHiremath Speaker shiremath@toh.caCanada Optimizing Hypertension Management Across the Lifespan Magdalena Madero Speaker madero.magdalena@gmail.comMexico Q&A 301 - 302																																																																ISN - APSN Joint Session IgA Nephropathy Study: Current and Perspective XueqingYu Speaker yuxueqing@gdph.org.cnChina Optimizing Management of Lupus Nephritis – The Clinical, The Bytes and The Bench DesmondYap Speaker desmondy@hku.hkHong Kong, China From Data to Discovery: Insights from ADPKD Registries Across the Asia-Pacific KornchanokVareesangthip Speaker kornchanok.ploy@gmail.comThailand Genetics of Chronic Kidney Disease in East Asians YukaSugawara Speaker ysuga-tky@m.u-tokyo.ac.jpJapan Q&A 303																																																																Dissecting the Kidney in Space: From Molecules to Microenvironments Applying Spatial Transcriptomics to Kidney Disease BERNHARDDUMOULIN Speaker bernhard.dumoulin@gmail.comUnited States A Systems Biology Approach to Tissue Mapping MatthiasKretzler Speaker kretzler@umich.eduUnited States Kidney Tissue Specific Gene Targeting TobiasHuber Speaker t.huber@uke.deGermany Envision Clinical Application AgnesFogo Speaker agnes.fogo@vanderbilt.eduUnited States Q&A 304																																																																Big Data Lab: Using Open Kidney Disease Data Resources for Research MatthiasKretzler Chair kretzler@umich.eduUnited States Pathomic-driven Tissue Interrogation: Harnessing Collaborative Intelligence and Data Integration for Diagnostic Innovation LauraBarisoni Speaker laura.barisoni@duke.eduUnited States Integrating Multiscale Data to Decode Kidney Disease Mechanisms NilsGehlenborg Speaker nils@hms.harvard.eduUnited States Exploring Single-cell and Spatial Datasets Using the Kidney Precision Medicine Project Atlas and Human Cell X Gene Tools NikkiBonevich Speaker bonevicn@med.umich.eduUnited States Training Session Introduction: Nephroseq and TranSMART for Global Kidney Data Mining HeatherAscani Speaker ascanihk@med.umich.eduUnited States Q&A 315																																																																ISN-KDIGO Joint Session: Implementing Updated KDIGO AKI/AKD Guidelines Worldwide Kent Doi Chair kentdoi@m.u-tokyo.ac.jpJapan Key Changes in AKI and AKD Definitions and Prognosis SamiraBell Speaker stbell@dundee.ac.ukUnited Kingdom Identifying and Preventing AKI and AKD in High-risk Scenarios MarliesOstermann Speaker m.ostermann@nhs.netUnited Kingdom Clinical Management of Acute Kidney Injury and Acute Kidney Disease VivekanandJha Speaker vjha@georgeinstitute.org.inIndia Optimizing Kidney Replacement Therapy in Acute Kidney Injury and Acute Kidney Disease NattachaiSrisawat Speaker drnattachai@yahoo.comThailand Q&A 501 - 502																																																																B Cell Targeting in Glomerular Disease A Role for Kidney Resident B/plasma Cells in Kidney Disease Progression? HeatherReich Speaker Heather.Reich@uhn.caCanada B Cell Activating Factor and A Proliferation-inducing Ligand Signaling in Glomerular Disease HongZhang Speaker hongzh@bjmu.edu.cnChina B Cell Targeted Therapies in Glomerular Diseases RichardLafayette Speaker czar@stanford.eduUnited States The Future of B Cell Therapies in the Treatment of Glomerular Diseases Jonathan Barratt Speaker jb81@leicester.ac.ukUnited Kingdom Q&A Session 503																																																																HIT! High Impact Clinical Trials 2 - New Insights Into Ongoing Trials AdeeraLevin Chair alevin@providencehealth.bc.caCanada Andrea Viecelli Chair andrea.viecelli@usz.chSwitzerland RobertoPecoits-Filho Chair roberto.pecoits@arborresearch.orgUnited States RESOLVE Trial: Sodium Concentration in Dialysis Populations — a Global Cluster Randomized Study MegJardine Speaker meg.jardine@sydney.edu.auAustralia Key Aspects of the VOICE Clinical Trial on Anemia in Dialysis Patients ShuchiAnand Speaker sanand2@stanford.eduUnited States TEACH-PD Cluster Randomized Controlled Trial: Targeted Education ApproaCH to improve Peritoneal Dialysis Outcomes JosephineChow Speaker Josephine.Chow@health.nsw.gov.auAustralia The Renal Life Cycle: Development, Maturity, and Decline HiddoLambers Heerspink Speaker H.J.Lambers.Heerspink@umcg.nlNetherlands Randomized Embedded Adaptive Platform Clinical Trial in South Asian Kidney Biopsy-proven Primary Glomerular Diseases: Multi-center, Multi-arm and Multi-stage- the Story So Far Joint Presentation Selvin Sundar RajMani Speaker selvinsr@gmail.comIndia SuceenaAlexander Speaker suceena@gmail.comIndia Q&A Main Hall
11 a.m. 12 p.m.	Industry Spotlight Session 10+12 ShoichiMaruyama Chair marus@med.nagoya-u.ac.jpJapan A Snapshot of aHUS ShoichiMaruyama Speaker marus@med.nagoya-u.ac.jpJapan The aHUS Clinical Picture AnujaJava Speaker ajava@wustl.eduUnited States Highlighting AHUS Associated With Triggers Wai Lim Speaker wai.lim@health.wa.gov.auAustralia Q&A Spotlight Stage 1																																																																Industry Spotlight Session 9 HidetoshiKanai Chair kanai8140002@yahoo.co.jpJapan Spotlight Stage 2
11:35 a.m. 12:35 p.m.	Plenary Lecture 2: Podocytopathies: Knowns and Unknowns (Paola Romagnani, Italy) Bywaters Award AkiraNishiyama Chair nishiyama.akira@kagawa-u.ac.jpJapan PaolaRomagnani Speaker paola.romagnani@unifi.itItaly Main Hall
12:45 p.m. 1:30 p.m.	Shared-Decision Making Spotlight Stage 1
12:50 p.m. 1:50 p.m.	Industry Symposium 17 YusukeSuzuki Chair yusuke@juntendo.ac.jpJapan Exploring the Role of APRIL in IgA Nephropathy: Pathogenesis to Progression Chee KayCheung Speaker ckc15@leicester.ac.ukUnited Kingdom HeatherReich Speaker Heather.Reich@uhn.caCanada 301 - 302																																																																Industry Symposium 14 VivekanandJha Chair vjha@georgeinstitute.org.inIndia Pathophysiology and Emerging Targeted Therapies in IgAN Yoshihito Nihei Speaker y-nihei@juntendo.ac.jpJapan Disease Pathways and Emerging Therapeutic Strategies in Primary Membranous Nephropathy VivekanandJha Speaker vjha@georgeinstitute.org.inIndia Mechanism-Based Therapeutic Advances in AMR in Kidney Transplantation SteveChadban Speaker Steve.Chadban@health.nsw.gov.auAustralia 303																																																																Industry Symposium 15 EdwinaBrown Chair e.a.brown@imperial.ac.ukUnited Kingdom A Patient’s Perspective: What Shared Decision-Making Really Means for Me TsutomuFuruzono Speaker furuzono@waka.kindai.ac.jpJapan Why SDM in Dialysis Still Falls Short: Understanding the Gaps YasuhiroKomatsu Speaker komayasu@gunma-u.ac.jpJapan Breaking Through Barriers: Practical Strategies to Make Shared Decision-Making Work EdwinaBrown Speaker e.a.brown@imperial.ac.ukUnited Kingdom 304																																																																Industry Symposium 13 KeiFukami Chair fukami@med.kurume-u.ac.jpJapan The Importance of Guideline Directed Therapy Christoph Wanner Speaker wanner_c@ukw.deGermany Long-term Management of Hyperkalemia with Safety NaokiKashihara Speaker kashinao@med.kawasaki-m.ac.jpJapan 315																																																																Industry Symposium 18 ShigeruShibata Chair shigeru.shibata@med.teikyo-u.ac.jpJapan Hypertension Management Aimed at Achieving Target Blood　Pressure : The Clinical Utility of Mineralocorticoid Receptor Antagonists HajimeNagasu Speaker hajimenagasu@kms-ndh.comJapan 501 - 502																																																																Industry Symposium 16 MotokoYanagita Chair motoy@kuhp.kyoto-u.ac.jpJapan Welcome & Introduction MotokoYanagita Speaker motoy@kuhp.kyoto-u.ac.jpJapan Orchestrating Excellence: KDIGO’s Guidance on the Management of IgA Nephropathy Sydney Tang Speaker scwtang@hku.hkHong Kong, China Setting the Tempo: The Importance of Early Diagnosis and Treatment in IgA Nephropathy Maria JoseSoler Speaker mjsoler01@gmail.comSpain A Harmonious Approach: Simultaneously Targeting Both Drivers VladoPerkovic Speaker vlado.perkovic@unsw.edu.auAustralia A Note of Hope: Reimagining the Outcomes for Patients With IgA Nephropathy MotokoYanagita Speaker motoy@kuhp.kyoto-u.ac.jpJapan Summary & Close MotokoYanagita Speaker motoy@kuhp.kyoto-u.ac.jpJapan 503
1:30 p.m. 2 p.m.	The Dialysis Games RashaDarwish Speaker dr.rasha-darwish@hotmail.comEgypt SourabhSharma Speaker drsourabh05@gmail.comIndia Spotlight Stage 2
2:10 p.m. 3:10 p.m.	Home Dialysis Revolution: Implementation Strategies and Outcomes Overcoming Barriers to Peritoneal Dialysis Implementation: The Role of the International Home Dialysis Consortium SimonDavies Speaker simonj.davies55@gmail.comUnited Kingdom Does Home Dialysis Improve Patient Outcomes? ChristopherChan Speaker christopher.chan@uhn.caCanada Beyond Traditional Boundaries: Wearable Artificial Kidneys and Portable Dialysis Technologies MarjorieFoo Speaker marjorie.foo.w.y@singhealth.com.sgSingapore Q&A 301 - 302																																																																ISN-PKDF Joint Session Introduction of the Lillian Jean Kaplan Prize for PKD & Award Presentation VicenteTorres Chair torres.vicente@mayo.eduUnited States Kaplan Prize winner; Disease modifying drugs for ADPKD: a rapidly evolving field. RonaldGansevoort Speaker r.t.gansevoort@umcg.nlNetherlands Platform trials in PKD: Opportunities and Challenges MegJardine Speaker meg.jardine@sydney.edu.auAustralia Is There a Role for SGLT2 Inhibitors and GLP Analogues in Treating PKD MichelChonchol Speaker Michel.Chonchol@comcast.netUnited States Q&A 303																																																																Why Primary and Community Care Matter for Kidney Health Shyam BihariBansal Chair drshyambansal@gmail.comIndia My Kidneys and Me: A Digital Platform for Empowering CKD Self-Management Community-Driven Innovation: Redesigning CKD Care in Ghana’s Health System Community-based Primary Care CKD Detection and Management in Thailand TalerngsakKanjanabuch Speaker golfnephro@hotmail.comThailand Group-based Care Models for Chronic Kidney Disease: A Latin American Perspective PaulaMarioli Speaker paulamarioli@renalida.comArgentina Q&A 304																																																																ISN-WKD Joint Session: Kidney Health for All — Caring for People, Protecting the Planet Li-LiHsiao Chair lhsiao@bwh.harvard.eduUnited States Key Takeaways from the 2026 WKD Editorial: Shaping the Future of Kidney Health DinaAbdellatif Speaker dina.abdellatif@gmail.comEgypt Kidney Health and Planetary Health: An Intricate Relationship GopalakrishnanNatarajan Speaker srigola751@yahoo.comIndia How the Patient Voice Shapes Kidney Care and Research NicoleScholes-Robertson Speaker nicole.scholes-robertson@sydney.edu.auAustralia Driving Change in Kidney Care: Lessons and Tools That Work Augusto CesarSoares dos Santos Junior Speaker acssjunior@hotmail.comBrazil Q&A 315																																																																ISN - EASD Joint Session: Crossroads of Nephrology and Diabetes: From Bench to Bedside Efficacy and Safety Results of Atrasentan in Patients With Iga Nephropathy on Sodium‚äìglucose Co-transporter 2 Inhibitors: Phase II, Randomized, Placebo-controlled, Crossover Trial (ASSIST) JanakaKaralliedde Speaker j.karalliedde@kcl.ac.ukUnited Kingdom Beyond HbA1c: Continuous Glucose Monitoring in Kidney Disease Care JuliaMader Speaker julia.mader@medunigraz.atAustria Drug Development in Diabetic Kidney Disease PeterRossing Speaker Peter.Rossing@regionh.dkDenmark Q&A 501 - 502																																																																Rare Kidney Disease Update Advances in C3G Diagnosis and Treatment HernánTrimarchi Speaker htrimarchi@hotmail.comArgentina Atypical Hemolytic Uremic Syndrome: Current Concepts and Management DavidKavanagh Speaker David.Kavanagh@newcastle.ac.ukUnited Kingdom Lupus LizLightstone Speaker l.lightstone@imperial.ac.ukUnited Kingdom Understanding IgA Nephropathy Today HeatherReich Speaker Heather.Reich@uhn.caCanada Q&A 503																																																																HIT! High Impact Clinical Trials 3 - In IgA Nephropathy and Others Sydney Tang Chair scwtang@hku.hkHong Kong, China Efficacy and Safety Results of Atrasentan in Patients With IgA Nephropathy on Sodium‚ äìglucose Co-transporter 2 Inhibitors: Phase II, Randomized, Placebo-controlled, Crossover Trial (Assist) HiddoLambers Heerspink Speaker H.J.Lambers.Heerspink@umcg.nlNetherlands Efficacy and Safety of a Targeted-release Formulation of Budesonide (HR19042 Capsules) in Patients With Primary IgA Nephropathy: A Randomized, Double-blind, Multicenter, Placebo-controlled Phase 2/3 Trial XiaobingYang Speaker yxb7829@163.comChina Efficacy and Safety of Iptacopan in Patients With Iga Nephropathy (IgAN): Final 24-month Results From the Phase Iii Applause-IgAN Study VladoPerkovic Speaker vlado.perkovic@unsw.edu.auAustralia ASPIRE Trial: Aspirin Use in Dialysis Patients in China XueqingYu Speaker yuxueqing@gdph.org.cnChina Q&A Main Hall																																																																Industry Spotlight Session 20 PeterZipfel Chair pzipfel@elevabiologics.comGermany BerndJilma Speaker bernd.jilma@meduniwien.ac.atAustria Spotlight Stage 1
2:30 p.m. 3 p.m.	Industry Spotlight Session 19 DavidCherney Chair david.cherney@uhn.on.caCanada Welcome and introduction DavidCherney Chair david.cherney@uhn.on.caCanada More than CKD: identifying and managing CV risk in patients With CKD DavidCherney Speaker david.cherney@uhn.on.caCanada Audience Q&A DavidCherney Moderator david.cherney@uhn.on.caCanada Toshiyuki Ko Moderator tkou-tky@umin.ac.jpJapan From the kidneys to the heart: practical management tools for CV risk in patients with CKD Toshiyuki Ko Speaker tkou-tky@umin.ac.jpJapan Audience Q&A DavidCherney Moderator david.cherney@uhn.on.caCanada Toshiyuki Ko Moderator tkou-tky@umin.ac.jpJapan Summary and close DavidCherney Chair david.cherney@uhn.on.caCanada Spotlight Stage 2
3:15 p.m. 3:45 p.m.	Industry Spotlight Session 21 HironoriKobayashi Chair hkoba1974@gmail.comJapan Spotlight Stage 2
3:50 p.m. 4:50 p.m.	Industry Digest: Insights into Latest Innovations from Scientific Leads Advancing the Next Wave of Therapies in Chronic Kidney Disease DustinLittle Speaker dustin.little@astrazeneca.comUnited States Effects of Finerenone on Biomarkers: Mechanistic Insights From Proteomic Analyses in Clinical Trials MarioBerger Speaker mario.berger@bayer.comGermany Future Directions in CRM Care: Advancing Research and Therapeutic Innovation AntonioGarreta Rufas Speaker antonio.garreta_rufas@boehringer-ingelheim.comGermany Innovative Strategies for Clinical Trial Design in IgAN JeffreyHafkin Speaker jeffrey.hafkin@otsuka-us.comUnited States Improving Outcomes in Complement-mediated Kidney Diseases Marianne Silkjær Nielsen Speaker Msn@compcure.orgSwitzerland Advancing Mechanistic Trials through Industry–Academia Collaboration: Insights from the REMODEL Trial ManuelMayrdorfer Speaker mumf@novonordisk.comDenmark Why? When? How? How to Maximize Patient Outcomes From the Start of Dialysis PeterRutherford Speaker peter.rutherford@vantive.comSwitzerland 301 - 302																																																																Building Trust and Equity in Indigenous Transplant Care Return to Country: Evaluating Health Service Bias and the Impact of Place-based Cultural Safety Initiatives KelliOwen Speaker kelli@anzdata.org.auAustralia ScottJones Speaker Scott.Jones@health.nsw.gov.auAustralia Equity in Action: Improving Access to Kidney Transplantation Through Community Partnerships in Rural, Remote, and Indigenous Communities AnuragSingh Speaker anuragsing@hotmail.comCanada Celebrating Cultural Inclusion and Safety in Academia and Medical Education LukeWilson Speaker luke.wilson@otago.ac.nzNew Zealand Q&A 303																																																																ISN-ISGD Joint Session Autoantibodies Targeting Podocyte-specific Antigens in Primary Nephrotic Syndrome TobiasHuber Speaker t.huber@uke.deGermany Insights from the Nephrotic Syndrome Study Network (NEPTUNE) and Cure Glomerulonephropathy (CureGN) groups AlessiaFornoni Speaker afornoni@med.miami.eduUnited States Podocyte-directed Progression of Kidney Injury in FSGS and DKD John CijiangHe Speaker cijiang.he@mssm.eduUnited States 304																																																																Innovating Kidney Trials: PROMs, New Designs, and Global Roadmaps MasaomiNangaku Chair mnangaku@m.u-tokyo.ac.jpJapan Opening Remarks and Session Overview AdeeraLevin Speaker alevin@providencehealth.bc.caCanada Overcoming the Bottleneck: Endpoint Selection in Phase 2 Kidney Trials Kai-UweEckardt Speaker kai-uwe.eckardt@charite.deGermany Integrating Patient-Reported Outcomes (PROMs) Using Patient-reported Outcomes to Improve Kidney Research and Care AllisonJaure Speaker allison.jaure@sydney.edu.auAustralia Rethinking Kidney Trials: Innovative Designs for Modern Research Questions MegJardine Speaker meg.jardine@sydney.edu.auAustralia Designing Better Kidney Trials Using Hierarchical Composite Endpoints HiddoLambers Heerspink Speaker H.J.Lambers.Heerspink@umcg.nlNetherlands Panel Discussion & Q&A Closing Remarks MasaomiNangaku Speaker mnangaku@m.u-tokyo.ac.jpJapan 311 - 312																																																																Navigating Ethical Challenges in End-of-Life Kidney Care DominiqueMartin Chair dominique.martin@deakin.edu.auAustralia HeatherAscani Speaker ascanihk@med.umich.eduUnited States JulioSaez-Rodriguez Speaker julio.saez@uni-heidelberg.deGermany LauraBarisoni Speaker laura.barisoni@duke.eduUnited States NikkiBonevich Speaker bonevicn@med.umich.eduUnited States Building Trust and Hope in Kidney Failure Care NoriakiKurita Speaker kuritanoriaki@gmail.comJapan How Advance Care Planning Supports Kidney Care Decisions KathrynDucharlet Speaker kducharlet@hotmail.comAustralia Patient Involvement in Shaping End-of-Life Kidney Care Policies ManvirVictor Speaker jmanvir@gmail.comMalaysia Q&A 315																																																																Hot Debate: Friend or Foe: SUMOylation in Kidney Injury and Repair SUMOylation of Podocin Reverses the Progression of Diabetic Kidney Disease PedroGeraldes Speaker Pedro.Geraldes@USherbrooke.caCanada SUMOylation Activates β-Catenin and Contributes to Kidney Fibrosis ZhengDong Speaker zdong@augusta.eduUnited States 501 - 502																																																																Paediatric Transplantation: Identifying Patients at Risk What Will Be the Future of Personalised Immunosuppression in Children? LarsPape Speaker Lars.Pape@uk-essen.deGermany Can We Prevent FSGS Recurrence in Children? PriyaVerghese Speaker pverghese@luriechildrens.orgUnited States What Is the Role of Anti-Nephrin Antibody in Pediatric Kidney Transplantation? YukoHamasaki Speaker yuhamasaki@med.toho-u.ac.jpJapan Q&A 503																																																																Hot Debate: Complement Inhibition vs Nefecon in IgA Nephropathy – Which First for Patients at Risk? Complement Inhibition Should Be Considered Before Nefecon in Patients With IgAN at Risk of Progression VladoPerkovic Speaker vlado.perkovic@unsw.edu.auAustralia Nefecon Should Be Considered Before Complement Inhibition in Patients With IgAN at Risk of Progression Main Hall
5 p.m. 6 p.m.	Industry Symposium 26 YusukeSuzuki Chair yusuke@juntendo.ac.jpJapan Evolving Landscape of IgA Nephropathy in 2026 and Beyond HongZhang Speaker hongzh@bjmu.edu.cnChina 303																																																																Industry Symposium 27 HITOSHISUZUKI Chair shitoshi@juntendo.ac.jpJapan Welcome & Introduction HITOSHISUZUKI Speaker shitoshi@juntendo.ac.jpJapan Understanding IgA Nephropathy Worldwide: Presentation, Progression, and Epidemiology ShikhaWadhwani Speaker shikha.wadhwani@northwestern.eduUnited States Mechanistic insights: Exploring the Role of Complement in IgA Nephropathy Jonathan Barratt Speaker jb81@leicester.ac.ukUnited Kingdom Panel Discussion and Q&A Session & Closing Remarks HITOSHISUZUKI Speaker shitoshi@juntendo.ac.jpJapan 304																																																																Industry Symposium 25 ParthaDas Chair parthadas@doctors.net.ukUnited Kingdom SharleneGreenwood Chair sharlene.greenwood@nhs.netUnited Kingdom Improving ESKD outcomes in Brazil BrunoZawadzki Speaker drbzawadzki@gmail.comBrazil Identifying and managing CKD in Africa KateBramham Speaker kate.bramham@kcl.ac.ukUnited Kingdom Q&A 315																																																																Industry Symposium 30 YOSHITAKAISAKA Chair isaka@kid.med.osaka-u.ac.jpJapan Transformative Insights from the DAPA-CKD Trial: Lessons for the Future of Kidney Care NaokiKashihara Speaker kashinao@med.kawasaki-m.ac.jpJapan 501 - 502																																																																From Seed to Impact: Building Global Kidney Care Capacity through ISN Grants Spotlight Stage 1
5:15 p.m. 6:15 p.m.	The Kidney Tank 3.0 - The Japanese Version Spotlight Stage 2
5:30 p.m. 6:15 p.m.	Your Nephrology Journey: Generalist or Specialist? AhadQayyum Speaker drahadqayyum@gmail.comPakistan Kanako Terakawa Speaker k.terakawa.med@gmail.comJapan NikolayBulanov Speaker nmbulanov@gmail.comRussia SabineKaram Speaker sabinejkaram@gmail.comUnited States YannickNlandu Speaker yannicknlandu@yahoo.frDemocratic Republic of Congo Spotlight Stage 1
5 p.m. 6 p.m.	Moderated Poster Session Exhibition Hall

30 March 2026

Time	Session

8:10 a.m. 9:10 a.m.	Industry Symposium 35 KatherineTuttle Chair Katherine.Tuttle@providence.orgUnited States Mechanistic Effects of Semaglutide on Kidney Disease in Type 2 Diabetes: The REMODEL trial KatherineTuttle Speaker Katherine.Tuttle@providence.orgUnited States Multiparametric Imaging and Tissue Transcriptomics to Unravel Mechanisms of Kidney Protection MatthiasKretzler Speaker kretzler@umich.eduUnited States GLP1s in Combination With Other Therapies and Applications in Clinical Practice BrendonNeuen Speaker bneuen@georgeinstitute.org.auAustralia The Future of GLP1s and Other Incretin-based Therapies for Kidney Disease MasaomiNangaku Speaker mnangaku@m.u-tokyo.ac.jpJapan 301 - 302																												Industry Symposium 33 JunOh Chair j.oh@uke.deGermany Welcome and introduction JunOh Speaker j.oh@uke.deGermany The burden of pediatric chronic kidney disease: Epidemiology, etiology and unmet needs KenjiIshikura Speaker lxkenzo@gmail.comJapan Studying pediatric chronic kidney disease: Challenges in evidence generation and clinical research HughMcCarthy Speaker hugh.mccarthy@health.nsw.gov.auAustralia The long-term consequences of childhood CKD: Growth, cardiovascular risk and adult outcomes JunOh Speaker j.oh@uke.deGermany Summary JunOh Speaker j.oh@uke.deGermany Discussion and Q&A 304																												Breakfast With the Editors: Publishing in Nephrology BradRovin Chair rovin.1@osu.eduUnited States PierreRonco Chair pierreronco@yahoo.frFrance Defining Vision and Scope PierreRonco Speaker pierreronco@yahoo.frFrance Introducing Kidney International Clinical Reports Journal SwapnilHiremath Speaker shiremath@toh.caCanada Choosing the Right Nephrology Journal PierreRonco Speaker pierreronco@yahoo.frFrance How Editors Assess Manuscripts BradRovin Speaker rovin.1@osu.eduUnited States Responding to Reviewer Comments JaiRadhakrishnan Speaker jr55@cumc.columbia.eduUnited States Dealing With Statistics in Kidney Research GermaineWong Speaker germaine.wong@health.nsw.gov.auAustralia From First Draft to First Author: Perspectives From a KI Editorial Fellow GriffithPerkins Speaker griffith.perkins@adelaide.edu.auAustralia Panel Discussion 313 - 314																												Industry Symposium 31 ChristineSkerka Chair christine.skerka@googlemail.comGermany Complement Deregulation in C3 Glomerulopathy : A Diagnostic Perspective PeterZipfel Speaker peter.zipfel@live.comGermany Targeted Therapy for C3 Glomerulopathy: Exciting Changes for Patients and Nephrologists MichaelWiesener Speaker michael.wiesener@uk-erlangen.deGermany C3 Glomerulopathy: Current Concepts and Emerging Therapeutic Strategies DineshKhullar Speaker drdineshkhullar@gmail.comIndia 315																												Industry Symposium 36 HITOSHISUZUKI Chair shitoshi@juntendo.ac.jpJapan Overview of Unmet Need in IgA Nephropathy and Disease Markers AdrianLiew Speaker draliew2@gmail.comSingapore Emerging Therapeutics Targets in IgAN: The Role of BAFF and APRIL SuceenaAlexander Speaker suceena@gmail.comIndia Targeting BAFF and APRIL with Atacicept RichardLafayette Speaker czar@stanford.eduUnited States 501 - 502																												Industry Symposium 34 SHOICHIMARUYAMA Chair mrsho111@gmail.comJapan Chair's welcome ShoichiMaruyama Chair marus@med.nagoya-u.ac.jpJapan Evolution of C3G and primary IC-MPGN disease understanding: from molecular mechanisms to addressing patient needs EdwinWong Speaker edwin.wong1@nhs.netUnited Kingdom A race against time: the value of an early and accurate diagnosis Seung HyeokHan Speaker hansh@yuhs.acSouth Korea Panel discussion: Looking to the future: time to support our patients ShoichiMaruyama Moderator marus@med.nagoya-u.ac.jpJapan Q&A and close ShoichiMaruyama Moderator marus@med.nagoya-u.ac.jpJapan 503
9:25 a.m. 10:55 a.m.	ISN-JSN Joint Session: Bioengineering the Kidney of the Future Shaping the Future of Kidney Regeneration TakashiYokoo Speaker tyokoo@jikei.ac.jpJapan Cutting-Edge Strategies in Kidney Regeneration JonathanHimmelfarb Speaker jonathan.himmelfarb@mssm.eduUnited States From iPS Cells to Kidneys: A Roadmap to Regeneration KenjiOsafune Speaker osafu@cira.kyoto-u.ac.jpJapan Breakthrough Discoveries Shaping the Future of Kidney Repair YunXia Speaker yunxia@ntu.edu.sgSingapore Q&A 301 - 302																								New Precision Therapies in Kidney Care Adeno-associated Viral Therapy in Kidney Diseases HiroyukiNakai Speaker nakaih@ohsu.eduUnited States CAR-T Cell Therapy in Lupus BradRovin Speaker rovin.1@osu.eduUnited States Cellular Immunotherapy in Kidney Transplantation TambiJarmi Speaker Jarmi.Tambi@mayo.eduUnited States TBC Q&A 303																								ISN-YN Joint Session: Youthful Insights on Aging Kidneys AhadQayyum Panel drahadqayyum@gmail.comPakistan BiancaDavidson Panel bianca.davidson@gmail.comSouth Africa HannahBeckwith Panel hannah.beckwith@kcl.ac.ukUnited Kingdom Winston Wing ShingFung Panel winstonwsfung@hotmail.comHong Kong, China Abstract winner TBD: highlighting young talent, providing opportunity to present Abstract winner TBD: highlighting young talent, providing opportunity to present Molecular Mechanisms of Kidney Aging: From Bench to Bedside TakeshiYamamoto Speaker tyamamoto@kid.med.osaka-u.ac.jpJapan Rethinking Goals of Care in Elderly Dialysis Patients HannahBeckwith Speaker hannah.beckwith@kcl.ac.ukUnited Kingdom Providing Care for the Aging Kidney in Low-resource Settings AhadQayyum Speaker drahadqayyum@gmail.comPakistan Synergy in Senescence: New Perspectives on Kidney Aging TakeshiYamamoto Speaker tyamamoto@kid.med.osaka-u.ac.jpJapan 304																								The ISN Journals Editorial Session: The Best of 2025 KI and KI Reports Articles GermaineWong Chair germaine.wong@health.nsw.gov.auAustralia Kidney International in Focus: Annual Highlights PierreRonco Speaker pierreronco@yahoo.frFrance ISN-KI Fellows: Showcasing Excellence, Part 1 — Pediatrics GabrielCara-Fuentes Speaker Gabriel.CaraFuentes@NationwideChildrens.orgUnited States ISN-KI Fellows: Showcasing Excellence, Part 2 — Clinical Nephrology SaharKoubar Speaker skoubar@umn.eduUnited States ISN-KI Fellows: Showcasing Excellence Part 3 — Epidemiology & Clinical Trials DavidTunnicliffe Speaker david.tunnicliffe@sydney.edu.auAustralia ISN-KI Fellows: Showcasing Excellence, Part 4 — Basic and Translational Science NahidTabibzadeh Speaker nahid.tabibzadeh@inserm.frFrance Kidney International Reports in Focus: Annual Highlights JaiRadhakrishnan Speaker jr55@cumc.columbia.eduUnited States Kidney International Reports in Focus: Annual Highlights SumitMohan Speaker mohan.sumit@gmail.comUnited States Kidney International Reports in Focus: Annual Highlights SumitMohan Speaker mohan.sumit@gmail.comUnited States Celebrating Excellence: Best Reviewer Awards Presentation BradRovin Speaker rovin.1@osu.eduUnited States Presentation of Basic Science Awards (Early Career Researcher Awards) BERNHARDDUMOULIN Speaker bernhard.dumoulin@gmail.comUnited States Presentation of Clinical Science Awards (Early Career Researcher Awards) Louis-CharlesDesbiens Speaker louischarles.desbiens@gmail.comCanada ISN-KI Fellows: Where Are They Now? GermaineWong Speaker germaine.wong@health.nsw.gov.auAustralia 315																								Integrating Care for Cardiovascular-Kidney-Metabolic Health Across the Lifespan Is Kidney Dysfunction in Heart Failure More Than Just Low Cardiac Output? BrendonNeuen Speaker bneuen@georgeinstitute.org.auAustralia Is Metabolic Dysfunction in Cardiovascular-Kidney-Metabolic Syndrome More Than Just Hyperglycemia and Obesity? HiddoLambers Heerspink Speaker H.J.Lambers.Heerspink@umcg.nlNetherlands Kidney at the Center of Conservative Kidney Management Syndrome MasaomiNangaku Speaker mnangaku@m.u-tokyo.ac.jpJapan What’s Next in Cardiovascular-Kidney-Metabolic Therapy? RobertoPecoits-Filho Speaker roberto.pecoits@arborresearch.orgUnited States Q&A 501 - 502																								Understanding and Treating Complement-Mediated Glomerular Disease Genetic Complementopathies and Kidney Disease AnujaJava Speaker ajava@wustl.eduUnited States Applying Precision Medicine to Glomerular Disorders JonathanHimmelfarb Speaker jonathan.himmelfarb@mssm.eduUnited States Complement and IgA Nephropathy AdrianLiew Speaker draliew2@gmail.comSingapore Complement and Anti-Neutrophil Cytoplasmic Antibody-associated Vasculitis RosnawatiYahya Speaker rosnayahya@gmail.comMalaysia Q&A 503																								HIT! High Impact Clinical Trials 4 KeiFukami Chair fukami@med.kurume-u.ac.jpJapan LizLightstone Chair l.lightstone@imperial.ac.ukUnited Kingdom Effect of a 12-week Intradialytic Cycling Intervention on Hemodialysis-induced Myocardial Stunning: A Multi-centre Randomized Controlled Trial ClaraBohm Speaker cbohm@sogh.mb.caCanada Effect of Finerenone on Circulating Biomarkers: A CONFIDENCE Analysis MarioBerger Speaker mario.berger@bayer.comGermany Effect of Simultaneous Initiation of Finerenone and Empagliflozin on Urinary Albumin-to-creatinine Ratio by Age and Sex in the CONFIDENCE Trial RajivAgarwal Speaker ragarwal@iu.eduUnited States Estimated Glomerular Filtration Rate, Systolic Blood Pressure, and Urinary Albumin-to-creatinine Ratio — Unravelling the Interplay in Combination: Findings From the CONFIDENCE Trial RajivAgarwal Speaker ragarwal@iu.eduUnited States Lowering-Hyperuricemia Treatment on Cardiovascular Outcomes in Peritoneal Dialysis Patients: A Prospective, Multicenter, Double Blind Randomized Controlled Trial Naya Huang Speaker huangnaya@163.comChina Main Hall
11 a.m. 11:30 a.m.	Translating Knowledge Into Action: Implementing the ISN i3C CKDu Toolkit for Global Impact Understanding the CKDu Challenge: A Global Health Priority ErangaWijewickrama Speaker erangasw@gmail.comSri Lanka Inside the ISN i3C CKDu Toolkit: Structure, Stages, and Key Components Ana CatalinaAlvarez Elias Speaker anacatalina.alvarezelias@rriny.comUnited States From Knowledge to Action: Implementing the Toolkit for Global Impact Magdalena Madero Speaker madero.magdalena@gmail.comMexico Spotlight Stage 1																																																																Industry Spotlight Session 39 JosephineChow Chair Josephine.Chow@health.nsw.gov.auAustralia Q & A Session JosephineChow Moderator Josephine.Chow@health.nsw.gov.auAustralia Spotlight Stage 2
11:35 a.m. 12:35 p.m.	Plenary Lecture 3: The Potential of Polypills in CKD (Anthony Rodgers, Australia) LilyMushahar Chair lilymushahar@gmail.comMalaysia MotokoYanagita Chair motoy@kuhp.kyoto-u.ac.jpJapan RobertKalyesubula Chair rkalyesubula@gmail.comUganda AnthonyRodgers Speaker arodgers@georgeinstitute.orgAustralia Main Hall
12:45 p.m. 1:15 p.m.	Social Media Impacts Nephrology Clinical Practice CristinaPopa Speaker cristina.adriana.popa90@gmail.comRomania DIVYABAJPAI Speaker divyaa24@gmail.comIndia Spotlight Stage 1
12:50 p.m. 1:50 p.m.	Industry Symposium 47 BradRovin Chair rovin.1@osu.eduUnited States Intro + IgAN Case: Global Perspective BradRovin Speaker rovin.1@osu.eduUnited States IgAN Case: China Perspective HongZhang Speaker hongzh@bjmu.edu.cnChina IgAN Case: Japan Perspective HITOSHISUZUKI Speaker shitoshi@juntendo.ac.jpJapan 301 - 302																												Industry Symposium 44 YusukeSuzuki Chair yusuke@juntendo.ac.jpJapan Welcome and introduction YusukeSuzuki Speaker yusuke@juntendo.ac.jpJapan Audience pooling Chee KayCheung Speaker ckc15@leicester.ac.ukUnited Kingdom Recent guidelines updates in IgAN-The rationale Chee KayCheung Speaker ckc15@leicester.ac.ukUnited Kingdom The old and the new to approaching treatment SaynaNorouzi Speaker sayna.nrz@gmail.comUnited States Summary and close YusukeSuzuki Speaker yusuke@juntendo.ac.jpJapan 303																												Industry Symposium 45 MasaomiNangaku Chair mnangaku@m.u-tokyo.ac.jpJapan Welcome & Introductions MasaomiNangaku Speaker mnangaku@m.u-tokyo.ac.jpJapan UACR: The hidden marker of heart and kidney risk PamelaKushner Speaker pamkushner@hotmail.comUnited States RobertoPecoits-Filho Speaker roberto.pecoits@arborresearch.orgUnited States Live Q&A MasaomiNangaku Moderator mnangaku@m.u-tokyo.ac.jpJapan The Impact of RAAS Dysregulation in Cardiorenal Disease Sydney Tang Speaker scwtang@hku.hkHong Kong, China Live Q&A MasaomiNangaku Moderator mnangaku@m.u-tokyo.ac.jpJapan Closing Remarks MasaomiNangaku Chair mnangaku@m.u-tokyo.ac.jpJapan 304																												Industry Symposium 43 AshokSarin Chair drashoksarin@gmail.comIndia Paradigm Shift in Anemia Management: From ESAs to HIF-PHIs Prem PrakashVarma Speaker varmapp123@rediffmail.comIndia Real World Evidence with Desidustat: India's Contribution to the Global HIF Story DineshKhullar Speaker drdineshkhullar@gmail.comIndia Panel discussion - Optimizing Outcomes with HIF-PHIs in CKD Anemia ManishMalik Moderator navyaanshumanish@gmail.comIndia Narayan Prasad Panel narayan.nephro@gmail.comIndia SandipBhattacharya Panel sandipkb65@gmail.comIndia DibyaSingh Shah Panel dibyasingh@hotmail.comNepal D SBhadauria Panel speaker@doc.comIndia 315																												Industry Symposium 48 NaokiSato Chair nms-ns@nms.ac.jpJapan RajivAgarwal Chair ragarwal@iu.eduUnited States Welcome & Introduction NaokiSato Speaker nms-ns@nms.ac.jpJapan Early Action, Stronger Protection BrendonNeuen Speaker bneuen@georgeinstitute.org.auAustralia Lower UACR, Optimized Outcomes RajivAgarwal Speaker ragarwal@iu.eduUnited States Finerenone, a CKM Pillar Jozine TerMaaten Speaker j.m.ter.maaten@umcg.nlNetherlands Changing Trajectories in Practice KeizoKanasaki Speaker kkanasakidr@gmail.comJapan Q&A and Closing Remarks / Panel Discussion NaokiSato Speaker nms-ns@nms.ac.jpJapan RajivAgarwal Speaker ragarwal@iu.eduUnited States 501 - 502																												Industry Symposium 46 YOSHITAKAISAKA Chair isaka@kid.med.osaka-u.ac.jpJapan Welcome and introduction YOSHITAKAISAKA Chair isaka@kid.med.osaka-u.ac.jpJapan Pathophysiology of C3G and Importance of Early Diagnosis YOSHITAKAISAKA Chair isaka@kid.med.osaka-u.ac.jpJapan Case studies: Different Patient Profiles CarlaNester Speaker carla-nester@uiowa.eduUnited States DavidKavanagh Speaker David.Kavanagh@newcastle.ac.ukUnited Kingdom Paul Brinkkötter Speaker paul.brinkkoetter@uk-koeln.deGermany Guidelines and Redefining Standard of Care YOSHITAKAISAKA Moderator isaka@kid.med.osaka-u.ac.jpJapan Audience Q&A YOSHITAKAISAKA Moderator isaka@kid.med.osaka-u.ac.jpJapan Summary and close YOSHITAKAISAKA Chair isaka@kid.med.osaka-u.ac.jpJapan 503
1 p.m. 2 p.m.	ISN Program Awards Spotlight Stage 2
1:15 p.m. 2 p.m.	Teach PD Spotlight Stage 1
2:10 p.m. 3:10 p.m.	Onco-nephrology: Navigating the Complexities of Kidney Disease in Patients With Cancer Cancer Screening in Kidney Transplant Recipients and Dialysis Patients Chi Yuen SimonCheung Speaker simoncycheung@gmail.comHong Kong, China Chronic Kidney Disease After Childhood Cancer Maria JoseSoler Speaker mjsoler01@gmail.comSpain Palliative Care in Cancer Patients With Kidney Disease: The Nephrologist's Role Q&A 301 - 302																					Pregnancy and Kidney Disease: A Rapid-fire Clinical Update ISN Train the Trainer Program MichelleHladunewich Chair michelle.hladunewich@sunnybrook.caCanada ShilpanjaliJesudason Chair shilpa.jesudason@sa.gov.auAustralia ISN Train-the-Trainer Program Overview ShilpanjaliJesudason Speaker shilpa.jesudason@sa.gov.auAustralia Rapid Fire Update 1 BalaWaziri Speaker balawaziri@gmail.comNigeria Rapid Fire Update 2 RashaShemies Speaker rashasamir@mans.edu.egEgypt Q&A MichelleHladunewich Moderator michelle.hladunewich@sunnybrook.caCanada 303																					ISN-YNC Session: Hot Debate: Can Xenotransplants and Stem Cells Replace Human Organ Donation? KornchanokVareesangthip Chair kornchanok.ploy@gmail.comThailand Introduction Proposition Speech 1 UgochiOnu Speaker ugochionu2008@gmail.comNigeria Opposition Speech 1 HirakuTsujimoto Speaker hira_to_ber3598@yahoo.co.jpJapan Rebuttal and Proposition Speech 2 I-RuChen Speaker angiogenesisbody@gmail.comTaiwan Rebuttal and Opposition Speech 2 Milagros MelissaFlores Fonseca Speaker flores1984md@yahoo.comMexico Audience Participation And Questions From Judges KenjiMatsui Judge kematsui@gmail.comUnited States NihalBashir Judge nmustafabashir@hotmail.comUnited Arab Emirates Voting and Summary Announcement of Winner and Prize Presentation 304																					World Veterinary Association AkiraYabuki Chair yabu@vet.kagoshima-u.ac.jpJapan What the Feline Kidney Teaches Us About Disease Development TakakoShimokawa Speaker t-shimokawa@ous.ac.jpJapan Animal Model–Based Training and Success in Interventional Nephrology BernardoMoguel González Speaker bernardomoguel@hotmail.comMexico Physiological Functions of a Cetacean-specific Aquaporin MiwaSuzuki Speaker suzuki.miwa@nihon-u.ac.jpJapan Q&A 315																					A Turning Point for Kidney Health: Global Impact of the WHO Resolution Implementing the WHO Resolution on Kidney Health MarcelloTonelli Speaker cello@ucalgary.caCanada From Resolution to Reality: Translating Evidence-Based CKD Therapies into Health Systems Panel Discussion 501 - 502																					ISN-ISPD Joint Session: Peritoneal Dialysis for Everyone, by Everyone, Everywhere LilyMushahar Chair lilymushahar@gmail.comMalaysia Supporting Patients in Choosing Peritoneal Dialysis as a Treatment Option RajnishMehrotra Speaker rmehrotr@uw.eduUnited States Person-centered Multidimensional Support for Patients on Home Dialysis RachaelWalker Speaker Rachael.walker@auckland.ac.nzNew Zealand Peritoneal Dialysis for Older Adults With Kidney Failure EdwinaBrown Speaker e.a.brown@imperial.ac.ukUnited Kingdom Hybrid Dialysis Models for Long-term Kidney Replacement Therapy YasuhikoIto Speaker yasuito57@gmail.comJapan Q&A 503																					ISN-Lancet Joint Session: New Series on Chronic Kidney Disease AdeeraLevin Chair alevin@providencehealth.bc.caCanada Why Equitable Kidney Care Remains a Global Challenge AndrejSkoberne Speaker andrej.b.skoberne@gmail.comSlovenia How Sex Differences Shape Kidney Health and Disease KateStevens Speaker kate.stevens@glasgow.ac.ukUnited Kingdom Opportunities for Delivering Equitable and Sustainable Kidney Care LuxiaZhang Speaker zhanglx@bjmu.edu.cnChina Q&A Main Hall																					Industry Spotlight Session 50 Atul DattatreyaSajgure Chair atulsajgure@yahoo.comIndia JavedVakil Chair jmvakvakil@gmail.comIndia T Balasubramaniyan Speaker mmcnephro@gmail.comIndia SiddharthLakhani Speaker siddharthlakhani1@gmail.comIndia Neuropathic Pain in CKD and Dialysis T Balasubramaniyan Speaker mmcnephro@gmail.comIndia Current and Emerging Therapies for Peripheral Neuropathy in CKD & Dialysis PratikDas Speaker drpratiktumpa.das70@gmail.comIndia Spotlight Stage 1
3:15 p.m. 3:45 p.m.	Squid Game Season 2: A Thrilling Game to Learn Kidney Genetics Spotlight Stage 1																																																																Industry Spotlight Session 51 RajivAgarwal Chair ragarwal@iu.eduUnited States The Pillar Perspective: A Deep Dive Into Clinical Evidence RajivAgarwal Speaker ragarwal@iu.eduUnited States Panel Discussion Multimodal Management of CKD and HF RajivAgarwal Moderator ragarwal@iu.eduUnited States Jozine TerMaaten Panel j.m.ter.maaten@umcg.nlNetherlands NaokiSato Panel nms-ns@nms.ac.jpJapan Spotlight Stage 2
3:50 p.m. 4:50 p.m.	From Ground Zero: Building Kidney Transplant Programs in Resource-limited Settings Paediatric Transplantation in LMICs: Building Family-Centered Infrastructure PriyaPais Speaker priyapais@gmail.comIndia Against the Odds: Establishing a Hospital-Based Transplant Program in Cameroon GloriaAshuntantang Speaker gloria.ash60@gmail.comCameroon Collaboration and Commitment: Malaysia's Journey Toward Transplant Independence Muhammad IqbalAbdul Hafidz Speaker fmeu6038@gmail.comMalaysia Q&A 301 - 302																					The Global Kidney Health Atlas: Advancing Equity and Excellence in Kidney Care Worldwide Opening & Session Introduction AdeeraLevin Chair alevin@providencehealth.bc.caCanada Tracking Kidney Care Capacity: The ISN-Global Kidney Health Atlas 2025 Update SomkanyaTungsanga Speaker s.tungsanga@gmail.comCanada Regional Perspectives: Gaps and Successes in Kidney Care Delivery ArpanaIyengar Speaker arpanaiyengar@gmail.comIndia Innovation & Collaboration for Better Kidney Health AminuBello Speaker aminu1@ualberta.caCanada Future Directions: Questions and Closing Remarks MasaomiNangaku Speaker mnangaku@m.u-tokyo.ac.jpJapan 303																					ISN-IPNA session Emerging Treatments for Pediatric Nephrotic Syndrome KoichiNAKANISHI Speaker knakanis@cs.u-ryukyu.ac.jpJapan Therapies for Nephrotic Syndrome: Short‑Term Impact, Long‑Term Promise Identify opportunities to integrate short‑term treatment gains with long‑term management strategies RulanParekh Speaker rulan.parekh@wchospital.caCanada What Clinicians Should Know About Anti-CD20 Monoclonal Antibodies in Childhood Nephrotic Syndrome Eugene Yu HinChan Speaker genegene.chan@gmail.comHong Kong, China Q&A 304																					Autoantibody-mediated Kidney Disease Anti-nephrin Mediated Podocytopathy Felicitas E.Hengel Speaker f.hengel@uke.deGermany PLA2R Epitope Pairing is Essential for Complement Activation in Membranous Nephropathy Cheng-LungKu Speaker clku@cgu.edu.twTaiwan What’s New in Anti-GBM Antibody Research Ming-huiZhao Speaker mhzhao@bjmu.edu.cnChina Q&A 313 - 314																					ISN–DICG Joint Session: Confronting Organ Trafficking — Policy, Ethics, and Prevention Mandatory Reporting of Suspicious Transplant-related Cases Maria AmaliaMatamoros Speaker amalia.matamoros@gmail.comCosta Rica Incentives to Reduce Organ Shortage KhalidaBulhan - Soki Speaker drkbsoki@gmail.comKenya Addressing Inequities to Prevent Organ Trafficking and Transplant Tourism LiliaCervantes Speaker Lilia.Cervantes@cuanschutz.eduUnited States Q&A 315																					Glomerular Disease Beyond the Kidney: Extraglomerular Manifestations Patient-reported Outcomes in Glomerular Disease: Considering the Whole Person MichelleO'Shaughnessy Speaker michelleoshaugh@gmail.comIreland Infectious Complications in Primary Glomerular Disease: Ensuring the Cure Isn’t Worse Than the Disease BalazsOdler Speaker balazs.odler@medunigraz.atAustria Cardiovascular Disease in Primary Glomerular Diseases: Quantifying and Reducing Risk MarkCanney Speaker mcanney@toh.caCanada Q&A 501 - 502																					ISN-ADQI Joint Session: Implementation Science and AKI in Acute Kidney Care MarliesOstermann Chair m.ostermann@nhs.netUnited Kingdom Why Implementation Science Matters in Acute Kidney Care YuvaramReddy Speaker yuvaram.reddy@pennmedicine.upenn.eduUnited States What Is the Acute Disease Quality Initiative (ADQI) and Why Do We Need ADQI XXXV? MarliesOstermann Speaker m.ostermann@nhs.netUnited Kingdom What Did We Learn From ADQI XXXV? OleksaRewa Speaker rewa@ualberta.caCanada Q&A 503																					Anemia Care in CKD: Recent Evidence and Future Directions Implementing Updated KDIGO Recommendations for CKD Anemia WolfgangWinkelmayer Speaker winkelma@bcm.eduUnited States Why CKD Anemia Care Differs Across Regions SunitaBavanandan Speaker sbavanandan@gmail.comMalaysia Beyond Erythropoiesis-stimulating Agents and Iron: Navigating the Future of Anemia of Chronic Kidney Disease Management Kai-UweEckardt Speaker kai-uwe.eckardt@charite.deGermany Q&A Main Hall
5 p.m. 6 p.m.	Industry Symposium 59 TakashiYokoo Chair tyokoo@jikei.ac.jpJapan Welcome and introduction From evidence to practice: SGLT2 inhibitors as a foundational treatment for patients With CKD BeatrizFernandez-Fernandez Speaker bfernandez@fjd.esSpain Prompt action in CKD: increasing treatment benefits for your patients with CKD Iande Boer Speaker deboer@uw.eduUnited States The hidden burden: managing cardiovascular risk in patients with CKD BrendonNeuen Speaker bneuen@georgeinstitute.org.auAustralia Audience Q&A Summary and close 301 - 302																					Industry Symposium 56 MotokoYanagita Chair motoy@kuhp.kyoto-u.ac.jpJapan The Significance of Potassium Management in CKD Treatment HidekiYokoi Speaker yokoih@kuhp.kyoto-u.ac.jpJapan 303																					Industry Symposium 57 MasaomiNangaku Chair mnangaku@m.u-tokyo.ac.jpJapan The Future of Lupus Nephritis: Achieving Renal Protection Through Proteinuria Control ShoichiMaruyama Speaker marus@med.nagoya-u.ac.jpJapan A New Era in Lupus Nephritis: Clinical Evidence and Therapeutic Positioning of Triple Therapy KeijuHiromura Speaker hiomura@gunma-u.ac.jpJapan 304																					Industry Symposium 55 Optimal Timing of Treatment Initiation and Monitoring Strategies for Fabry Disease Patients in Korea Eun HuiBae Speaker baedak@hanmail.netSouth Korea New Therapeutic Strategies for Fabry Disease HidekiFujii Speaker fhideki@med.kobe-u.ac.jpJapan 315																					Industry Symposium 58 HITOSHISUZUKI Chair shitoshi@juntendo.ac.jpJapan Tonsillectomy for IgA nephropathy MikiTakahara Speaker miki@asahikawa-med.ac.jpJapan Impact of Intestinal Barrier Dysfunction on IgA Deposition in the Glomeruli KojiHase Speaker hase.a6@keio.jpJapan 503																					Moderated Poster Session Exhibition Hall																					Clinical Trials Demystified: How ISN TrialWatch and the Guide for Everyone Empower Understanding and Participation Building Clinical Trial Awareness in the Kidney Community Andrea Viecelli Speaker andrea.viecelli@usz.chSwitzerland ISN TrialWatch: Bringing the Latest Evidence to the Kidney Community MeganBorkum Speaker mborkum@gmail.comCanada The ISN Guide for Everyone: Demystifying Clinical Research AdeeraLevin Speaker alevin@providencehealth.bc.caCanada Spotlight Stage 1																					Support Your Non-Physician Kidney Care Allies: Launch of a Global Curriculum by ISN Emerging Leaders cohort 3 Spotlight Stage 2
5:30 p.m. 6 p.m.	When Disasters Are the Norm: A 2050 Kidney Care Simulation RDPWG Session Micro-scenario 1: Water Disruption — a 2050 Simulation Vignette SayakaIshigaki Speaker ishigaki@hama-med.ac.jpJapan Micro-Scenario 2: Digital Outage and Logistics Delay Chia-TerChao Speaker b88401084@gmail.comTaiwan A Set of “Resilience Provocations” for 2050 Kyung DonYoo Speaker ykd9062@gmail.comSouth Korea Spotlight Stage 1																																																																Women in Nephrology: Home Dialysis Perspectives From Three Regions Women in Nephrology USA: Regional Experience and Insights MalaSachdeva Speaker msachdeva@northwell.eduUnited States Women in Nephrology in India: Progress, Barriers, and Opportunities UrmilaAnandh Speaker uanandh@gmail.comIndia Women in Nephrology in Africa: Lessons Learned KhalidaBulhan - Soki Speaker drkbsoki@gmail.comKenya Questions and Answers Spotlight Stage 2

31 March 2026

Time	Session

8 a.m. 9 a.m.	Industry Symposium 61 MotokoYanagita Chair motoy@kuhp.kyoto-u.ac.jpJapan Revisiting MR-Mediated Electrolyte Imbalance at the Tissue Level: Implications for MR Blockade and JSH2025 Guidelines KentoKitada Speaker kitada.kento@kagawa-u.ac.jpJapan 303
9:10 a.m. 10:40 a.m.	Kidney Health in Pregnancy: Solutions to a Growing Challenge KateBramham Chair kate.bramham@kcl.ac.ukUnited Kingdom Global Snapshot of Pregnancy-associated Acute Kidney Injury: Results From the 2025 Global Survey KatherineClark Speaker katherine.clark@kcl.ac.ukUnited Kingdom Improving Pregnancy-related Kidney Disease Diagnosis RashaShemies Speaker rashasamir@mans.edu.egEgypt Emerging Strategies for CKD Care During Pregnancy DIVYABAJPAI Speaker divyaa24@gmail.comIndia Implementing Simple, Scalable, Co-designed Solutions for Kidney Health in Policy and Practice StephenMutiso Speaker stephenmutiso@gmail.comKenya Q&A 301 - 302				ISN-TTS Joint Session: Maximising Opportunities and Resources in Kidney Transplant Care GeorginaIrish Chair georgina@anzdata.org.auAustralia Using Causal Inference to Study Gender Gaps in Transplant Access JessicaHarding Speaker jessica.harding@emory.eduUnited States Pragmatic Medicine: Learning From the Indian Experience Shyam BihariBansal Speaker drshyambansal@gmail.comIndia Helping Patients Manage Medications and Complex Health Systems GermaineWong Speaker germaine.wong@health.nsw.gov.auAustralia Reducing the Environmental Footprint in Transplantation IvoLaranjinha Speaker ivolaranjinha@gmail.comPortugal Q&A 303				Genetic Testing in Kidney Disease: Interpretation and Patient Perspectives Genetic Pretesting — Is More Always Better? RoserTorra Speaker rtorra@fundacio-puigvert.esSpain The Test: Nephro-genomic Board Simulation: Variant Scientist X Genetic Nephrologist DanielGale Speaker d.gale@ucl.ac.ukUnited Kingdom Risk Alleles and Low-penetrance Variants in Nephrology: Gaps in Evidence JanewitWongboonsin Speaker jwongboonsin@gmail.comThailand The Patient Voice SusieGear Speaker susiegear@alportuk.orgUnited Kingdom Q&A Main Hall
11 a.m. 12 p.m.	ISN-JSDT Joint Session TadashiTomo Chair tomo@oita-u.ac.jpJapan Dialysis Membranes and Patient Survival AbeMasanori Speaker abe.masanori@nihon-u.ac.jpJapan Sex-specific Outcomes and Prognosis in Dialysis Care SaoriNishio Speaker saorin@med.hokudai.ac.jpJapan Practical Aspects of Preserving the Peritoneal Dialysis Membrane Ana Elizabeth Figueiredo Speaker anaef@pucrs.brBrazil 301 - 302			Climate and Conflict: Protecting Kidney Health Amid Global Disruptors Diabetes Masculinises the Risk for Progressive Nephropathy of Indigenous Australian Females With CKD: The CKD.QLD Experience WendyHoy Speaker w.hoy@uq.edu.auAustralia Green Nephrology: Rethinking Sustainability in Dialysis Systems Winston Wing ShingFung Speaker winstonwsfung@hotmail.comHong Kong, China Heat, Sweat, and Silence: Two Decades of Uncovering Mesoamerican Nephropathy RamonGarcia Trabanino Speaker rgtrab@gmail.comEl Salvador When Funding Fades: Geopolitical Shifts and Kidney Health in Fragile Settings GraceKansiime Speaker graekan@gmail.comUganda Q&A 303			Cutting Edge Science in Diabetic Kidney Disease Complement Activation in Diabetic Kidney Disease MinChen Speaker chenmin74@sina.comChina Applying Spatial Transcriptomics to Diabetic Kidney Disease Research BERNHARDDUMOULIN Speaker bernhard.dumoulin@gmail.comUnited States Applying Metabolomics to Understand Diabetic Kidney Disease ReikoInagi Speaker inagi-r@m.u-tokyo.ac.jpJapan Q&A 304			ISN-JSN-APSN Joint Session: Delivering Kidney Care in Humanitarian Crises AliAbu-Alfa Chair abualfa@aub.edu.lbLebanon KeiFukami Chair fukami@med.kurume-u.ac.jpJapan LilyMushahar Chair lilymushahar@gmail.comMalaysia The ISN Role in Humanitarian Kidney Care AliAbu-Alfa Speaker abualfa@aub.edu.lbLebanon Disaster Preparedness in Kidney Care: Pitfalls and Solutions SerhanTuglular Speaker serhantuglular@yahoo.comTurkey Earthquake Disaster: Lessons Learnt from Japan KeiFukami Speaker fukami@med.kurume-u.ac.jpJapan Resilient Kidney Care: Adaptation and Recovery After a Disaster SabineKaram Speaker sabinejkaram@gmail.comUnited States Q&A Main Hall
12:10 p.m. 1:10 p.m.	Plenary Lecture 4: Hugh de Wardener Lecture - Creating Paradigm Shifts in Medical Diagnostics Using Liquid Biopsy (Dennis Lo, Hong Kong, China) Yuk Ming DennisLO Speaker loym@cuhk.edu.hkHong Kong, China Main Hall